IBDEI1S5 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,30246,0)
 ;;=C79.71^^118^1503^17
 ;;^UTILITY(U,$J,358.3,30246,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30246,1,3,0)
 ;;=3^Secondary malignant neoplasm of right adrenal gland
 ;;^UTILITY(U,$J,358.3,30246,1,4,0)
 ;;=4^C79.71
 ;;^UTILITY(U,$J,358.3,30246,2)
 ;;=^5001356
 ;;^UTILITY(U,$J,358.3,30247,0)
 ;;=C79.72^^118^1503^10
 ;;^UTILITY(U,$J,358.3,30247,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30247,1,3,0)
 ;;=3^Secondary malignant neoplasm of left adrenal gland
 ;;^UTILITY(U,$J,358.3,30247,1,4,0)
 ;;=4^C79.72
 ;;^UTILITY(U,$J,358.3,30247,2)
 ;;=^5001357
 ;;^UTILITY(U,$J,358.3,30248,0)
 ;;=C77.5^^118^1503^8
 ;;^UTILITY(U,$J,358.3,30248,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30248,1,3,0)
 ;;=3^Secondary malignant neoplasm of intrapelvic nodes
 ;;^UTILITY(U,$J,358.3,30248,1,4,0)
 ;;=4^C77.5
 ;;^UTILITY(U,$J,358.3,30248,2)
 ;;=^267319
 ;;^UTILITY(U,$J,358.3,30249,0)
 ;;=C48.2^^118^1504^24
 ;;^UTILITY(U,$J,358.3,30249,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30249,1,3,0)
 ;;=3^Malignant neoplasm of peritoneum, unspecified
 ;;^UTILITY(U,$J,358.3,30249,1,4,0)
 ;;=4^C48.2
 ;;^UTILITY(U,$J,358.3,30249,2)
 ;;=^5001122
 ;;^UTILITY(U,$J,358.3,30250,0)
 ;;=C45.0^^118^1504^30
 ;;^UTILITY(U,$J,358.3,30250,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30250,1,3,0)
 ;;=3^Mesothelioma of pleura
 ;;^UTILITY(U,$J,358.3,30250,1,4,0)
 ;;=4^C45.0
 ;;^UTILITY(U,$J,358.3,30250,2)
 ;;=^5001095
 ;;^UTILITY(U,$J,358.3,30251,0)
 ;;=C38.4^^118^1504^25
 ;;^UTILITY(U,$J,358.3,30251,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30251,1,3,0)
 ;;=3^Malignant neoplasm of pleura
 ;;^UTILITY(U,$J,358.3,30251,1,4,0)
 ;;=4^C38.4
 ;;^UTILITY(U,$J,358.3,30251,2)
 ;;=^267140
 ;;^UTILITY(U,$J,358.3,30252,0)
 ;;=C41.9^^118^1504^16
 ;;^UTILITY(U,$J,358.3,30252,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30252,1,3,0)
 ;;=3^Malignant neoplasm of bone and articular cartilage, unsp
 ;;^UTILITY(U,$J,358.3,30252,1,4,0)
 ;;=4^C41.9
 ;;^UTILITY(U,$J,358.3,30252,2)
 ;;=^5000993
 ;;^UTILITY(U,$J,358.3,30253,0)
 ;;=C49.9^^118^1504^19
 ;;^UTILITY(U,$J,358.3,30253,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30253,1,3,0)
 ;;=3^Malignant neoplasm of connective and soft tissue, unsp
 ;;^UTILITY(U,$J,358.3,30253,1,4,0)
 ;;=4^C49.9
 ;;^UTILITY(U,$J,358.3,30253,2)
 ;;=^5001136
 ;;^UTILITY(U,$J,358.3,30254,0)
 ;;=C47.9^^118^1504^14
 ;;^UTILITY(U,$J,358.3,30254,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30254,1,3,0)
 ;;=3^Malig neoplasm of prph nerves and autonm nervous sys, unsp
 ;;^UTILITY(U,$J,358.3,30254,1,4,0)
 ;;=4^C47.9
 ;;^UTILITY(U,$J,358.3,30254,2)
 ;;=^5001121
 ;;^UTILITY(U,$J,358.3,30255,0)
 ;;=C43.9^^118^1504^15
 ;;^UTILITY(U,$J,358.3,30255,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30255,1,3,0)
 ;;=3^Malignant melanoma of skin, unspecified
 ;;^UTILITY(U,$J,358.3,30255,1,4,0)
 ;;=4^C43.9
 ;;^UTILITY(U,$J,358.3,30255,2)
 ;;=^5001015
 ;;^UTILITY(U,$J,358.3,30256,0)
 ;;=D03.9^^118^1504^29
 ;;^UTILITY(U,$J,358.3,30256,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30256,1,3,0)
 ;;=3^Melanoma in situ, unspecified
 ;;^UTILITY(U,$J,358.3,30256,1,4,0)
 ;;=4^D03.9
 ;;^UTILITY(U,$J,358.3,30256,2)
 ;;=^5001908
 ;;^UTILITY(U,$J,358.3,30257,0)
 ;;=C44.01^^118^1504^5
 ;;^UTILITY(U,$J,358.3,30257,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30257,1,3,0)
 ;;=3^Basal cell carcinoma of skin of lip
 ;;^UTILITY(U,$J,358.3,30257,1,4,0)
 ;;=4^C44.01
 ;;^UTILITY(U,$J,358.3,30257,2)
 ;;=^340464
 ;;^UTILITY(U,$J,358.3,30258,0)
 ;;=C44.02^^118^1504^35
 ;;^UTILITY(U,$J,358.3,30258,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30258,1,3,0)
 ;;=3^Squamous cell carcinoma of skin of lip
